Interventions for valvular disease and heart failure

Clinical impact of elevated tricuspid valve inflow gradients after transcatheter edge-to-edge tricuspid valve repair

EuroIntervention 2019;15:e1057-e1064. DOI: 10.4244/EIJ-D-19-00237

Martin Orban
Martin Orban1,2, MD; Mathias W. Orban1,2, MD; Daniel Braun1,2, MD; Simon Deseive1,2, MD; Danny Kupka1,2, MD; Thomas J. Stocker1,2, MD; Erik Bagaev2,3, MD; Nicole Karam4,3, MD, PhD; Christian Hagl2,3, MD; Steffen Massberg1,2, MD, PhD; Michael Nabauer1,2, MD; Jörg Hausleiter1,2, MD
1. Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany; 2. Munich Heart Alliance, Partner Site German Center for Cardiovascular Disease (DZHK), Munich, Germany; 3. Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, Munich, Germany; 4. European Hospital Georges Pompidou (Cardiology Department) and Paris Cardiovascular Research Center (INSERMU970), Paris, France

Aims: The aim of this study was to compare the outcome of patients with a post-procedural tricuspid valve gradient (TVG) of >3 mmHg vs ≤3 mmHg after transcatheter edge-to-edge tricuspid valve repair (TTVR).

Methods and results: Between March 2016 and October 2018 we treated 145 patients with severe tricuspid regurgitation (TR) with TTVR by placing 2.2±0.7 clips per patient. Device success (TR reduction ≥1° to at least moderate) was achieved in 125 patients (86.2%). TTVR resulted in an elevated TVG >3 mmHg in 25 (17.2%) patients. Device success (84% vs 86.7%, p=0.9), number of clips implanted (2.3±0.7 vs 2.2±0.7, p=0.33), clinical improvement including NYHA class (III/IV 24% vs 28%, p=0.92) and increase in six-minute walking test at one month (67 m [IQR 5-103 m] vs 56 m [IQR 8-97 m], p=0.93), mortality (HR 1.07, 95% CI: 0.43-2.65, plogrank=0.88) and the combined endpoint mortality and hospitalisation for heart failure at one year (HR 1.07, 95% CI: 0.46-2.48, plogrank=0.88) were similar between patients with a TVG >3 mmHg versus patients with a TVG ≤3 mmHg.

Conclusions: A small cohort of patients demonstrated an elevated TVG higher than 3 mmHg at discharge. This elevation had no impact on clinical improvement, mortality or hospitalisation for heart failure.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

chronic heart failurefemoralmitral valve repairtransthoracic echocardiogramtricuspid diseasettvr
Interventions for valvular diseaseInterventions for heart failureMitral valve replacement and repairTricuspid / Pulmonary valveChronic heart failure
Read next article
Mitral regurgitation severity predicts one-year therapeutic benefit of Tendyne transcatheter mitral valve implantation

Latest news